Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

MLA

Laura Capelli, et al. “Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.” Clinical Cancer Research, vol. 23, Apr. 2017, pp. 2195–202. EBSCOhost, https://doi.org/10.1158/1078-0432.ccr-16-0966.

APA

Laura Capelli, Rita Chiari, Elisabetta Petracci, Maximilian Papi, Dino Amadori, Daniele Calistri, Chiara Bennati, Matteo Canale, Nicoletta De Luigi, Lucio Crinò, Marita Mariotti, Claudia Casanova, Claudio Dazzi, Angelo Delmonte, Paola Ulivi, Vienna Ludovini, Elisa Chiadini, & Alessandro Gamboni. (2017). Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clinical Cancer Research, 23, 2195–2202. https://doi.org/10.1158/1078-0432.ccr-16-0966

Chicago

Laura Capelli, Rita Chiari, Elisabetta Petracci, Maximilian Papi, Dino Amadori, Daniele Calistri, Chiara Bennati, et al. 2017. “Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.” Clinical Cancer Research 23 (April): 2195–2202. doi:10.1158/1078-0432.ccr-16-0966.